en
svNotice of extraordinary general meeting in Xspray Pharma AB (publ)
Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per Thursday 22 November 2018, and who no later than on Thursday 22 November 2018, have given notice to the company of their intent to participate at the EGM, shall have the right to participate […]
Read moreXspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence
”It has taken us three years of work to come to these encouraging results and the excitement in the company is clearly present today. We will now take serious steps in order to develop the business and as our technology is now proven we will seek partners for the commercial launch of HyNap-Dasa”, says Per […]
Read moreRibbskottet AB increases its stake in Xspray Pharma
Ribbskottet AB has since Xspray’s introduction on First North in September 2017 been one of its ten largest owners. On September 24, 2018, it expanded its holding in the company through the purchase of a total of 223,000 shares. After the deal, Ribbskottet holds a total of 1,371,429 shares in Xspray, corresponding to 10.0 percent […]
Read moreXspray Pharma announces positive clinical data for its lead product candidate HyNap-Dasa
The completed clinical Phase I study examined HyNap-Dasa’s bioavailability compared to the dasatinib cancer drug, currently marketed as Sprycel for the treatment of chronic myeloid leukemia (CML). In the study, bioavailability of two different tablet formulations of HyNap-Dasa was tested in comparison with Sprycel tablets in 16 healthy subjects. The results are very positive and […]
Read moreXspray Pharma and NerPharMa deliver clinical trial material to HyNap-Dasa study
Xspray has contracted NerPharMa to produce materials for Xspray’s clinical program and finished products for future commercial sale. The material delivered to the HyNap-Dasa study is the first resulting from this collaboration. Xspray is developing HyNap-Dasa both as a fully equivalent version of Sprycel to be registered in the US under an Abbreviated New Drug […]
Read moreXspray Pharma gets go-ahead from the Swedish MPA for clinical study
“We are pleased with the progress of the project and following the decision of the MPA, we can now proceed with our plan for clinical studies,” commented Per Andersson, CEO of Xspray Pharma. The current study is intended to confirm the formulation of the product candidate HyNap-Dasa. The results will form the basis of the […]
Read moreXspray Pharma Chariman divests 4,000 shares to cover Danish capital gains tax on unrealised gains on Xspray Pharma shares
”As the tax is charged on unrealized capital gains solely on the holding of Xspray Pharma shares in my private holding company, I have decided to cover the tax by divesting the same kind of assets as released the tax. The divestment constitutes a minor share of my total holding and my faith in the […]
Read moreNotice of annual general meeting in Xspray Pharma AB (publ)
Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per Monday 7 May, 2018 and who no later than on Monday 7 May, 2018 have given notice to the company of their intent to participate at the AGM, shall have the right to participate […]
Read moreBulletin from the extraordinary general meeting of Xspray Pharma AB (publ)
Directed issue of shares The general meeting resolved, in accordance with the board of directors’ proposal, to carry out a directed issue of not more than 1,350,000 new shares, entailing an increase in the share capital of not more than SEK 1,350,000. The right to subscribe for the new shares in the directed issue shall, […]
Read moreNotice of extraordinary general meeting in Xspray Pharma AB (publ)
Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per Wednesday 14 February, 2018, and who, no later than on Wednesday 14 February, 2018, have given notice to the company of their intent to participate at the EGM, shall have the right to participate […]
Read more